Stepwise Decrease in Daptomycin Susceptibility in Clinical Staphylococcus aureus Isolates Associated with an Initial Mutation in rpoB and a Compensatory Inactivation of the clpX Gene
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Daptomycin is a lipopeptide antibiotic used clinically for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. The emergence of daptomycin-nonsusceptible S. aureus isolates during therapy is often associated with multiple genetic changes; however, the relative contributions of these changes to resistance and other phenotypic changes usually remain unclear. The present study was undertaken to investigate this issue using a genetically characterized series of four isogenic clinical MRSA strains derived from a patient with bacteremia before and during daptomycin treatment. The first strain obtained after daptomycin therapy carried a single-nucleotide polymorphism (SNP) in rpoB (RpoB A 477 D) that decreased susceptibility not only to daptomycin but also to vancomycin, β-lactams, and rifampin. Furthermore, the rpoB mutant exhibited pleiotropic phenotypes, including increased cell wall thickness, reduced expression of virulence traits, induced expression of the stress-associated transcriptional regulator Spx, and slow growth. A subsequently acquired loss-of-function mutation in clpX partly alleviated the growth defect conferred by the rpoB mutation without changing antibiotic susceptibility. The final isolate acquired three additional mutations, including an SNP in mprF (MprF S 295 L) known to confer daptomycin nonsusceptibility, and accordingly, this isolate was the only daptomycin-nonsusceptible strain of this series. Interestingly, in this isolate, the cell wall had regained the same thickness as that of the parental strain, while the level of transcription of the vraSR (cell wall stress regulator) was increased. In conclusion, this study illustrates how serial genetic changes selected in vivo contribute to daptomycin nonsusceptibility, growth fitness, and virulence traits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Waves of resistance: Staphylococcus aureus in the antibiotic era
Chambers, H. F., & DeLeo, F. R. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2200 · Cited by 2,718 · cited 2×
“aureus (MRSA) strains first in hospitals and later in the general community (1).”
BackgroundBayer, A. S., Schneider, T., & Sahl, H. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06819.x · Cited by 311 · cited 20×
“The same SNP was previously identified in DAP-NS strains isolated from the bloodstream of a daptomycin-treated patient with recalcitrant endocarditis (30, 31).”
BackgroundInfluentialImpact of rpoB Mutations on Reduced Vancomycin Susceptibility in Staphylococcus aureus
Watanabe, Y., Cui, L., Katayama, Y., Kozue, K., & Hiramatsu, K. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02144-10 · Cited by 127 · cited 2×
“However, as only the rpoB gene was sequenced, the possibility that additional unidentified mutations contributed to the reported phenotypes in these two studies could not be ruled out (38, 44).”
BackgroundRegulation of host hemoglobin binding by the Staphylococcus aureus Clp proteolytic system
Farrand, A. J., Reniere, M. L., Ingmer, H., Frees, D., & Skaar, E. P. (2013) · Journal of Bacteriology · doi:10.1128/jb.00505-13 · Cited by 56 · cited 1×
“aureus in animal models of infection (22, 23).”
BackgroundSelf-citation
Cited by
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
Miller, W. R., & Arias, C. A. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01054-w · Cited by 862
Antibiotic Resistance and the MRSA Problem
Vestergaard, M., Frees, D., & Ingmer, H. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0057-2018 · Cited by 490
Self-citationMechanism of Action and Resistance to Daptomycin in Staphylococcus aureus and Enterococci
Miller, W. R., Bayer, A. S., & Arias, C. A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026997 · Cited by 227
“…A621E, was associated with increased expression of the dlt operon and correlated with an increase in positive cell-surface charge, whereas RpoB mutations A621E and A477D were both linked to activation of cell-wall biosynthesis and increased cell-wall thickness (Cui et al. 2010; Bæk et al. 2015).”
Shen, T., Penewit, K., Waalkes, A., Xu, L., Salipante, S. J., Nath, A., & Werth, B. J. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa422 · Cited by 14
(2025) · doi:10.1128/msystems.01092-25 · Cited by 1
Metadata
- Authors
- Bæk, K. T., Thøgersen, L., Mogenssen, R. G., Mellergaard, M., Thomsen, L. E., Petersen, A., Skov, S., Cameron, D. R., Peleg, A. Y., & Frees, D.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2015-11
- Volume
- 59
- Issue
- 11
- Pages
- 6983-6991
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W1934668983
- Cited by
- 79
- References
- 4
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.